BBHC
RVMD icon

Brown Brothers Harriman & Co’s Revolution Medicines RVMD Stock Holding History

Brown Brothers Harriman & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Hold
15,000
– – 0.01% 298
2026
Q1 		$1.46M Buy
+15,000
New +$1.51M 0.01% 362

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Brown Brothers Harriman & Co's RVMD Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Revolution Medicines (RVMD) position steady in Q2 2026 at 15,000 shares worth $2.81M. The position accounts for 0.01% of the portfolio, ranked #298.

Brown Brothers Harriman & Co first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Brown Brothers Harriman & Co held 15,000 shares of Revolution Medicines worth $2.81M as of Q2 2026.
  • Brown Brothers Harriman & Co left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up 0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #298 holding.
  • Brown Brothers Harriman & Co first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.